Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093855 | 0.79 | KMT2A (0.48) | SLC6A4SLC6A2KCNH2LMNA | |
| SCHEMBL31587245 | 0.78 | NOS3 (0.56) | NOS3NOS2NOS1CYP2A6LMNA | |
| SCHEMBL12647715 | 0.78 | NOS3 (0.56) | NOS3NOS2NOS1CYP2A6LMNA | |
| SCHEMBL13283349 | 0.78 | NOS3 (0.56) | NOS3NOS2NOS1CYP2A6LMNA | |
| SCHEMBL22945605 | 0.77 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL15828598 | 0.77 | DHFR (0.33) | NOS3NOS2NOS1SLC6A4SLC6A2 | |
| SCHEMBL20465810 | 0.76 | NOS3 (0.54) | NOS3NOS2NOS1CYP2A6LMNA | |
| SCHEMBL17480023 | 0.76 | NOS3 (0.54) | NOS3NOS2NOS1CYP2A6LMNA | |
| SCHEMBL20465809 | 0.74 | LMNA (0.55) | NOS3NOS2NOS1CYP2A6LMNA | |
| SCHEMBL20124986 | 0.73 | NOS3 (0.50) | NOS3NOS2NOS1CYP2A6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | NOS3 2969/4885NOS2 3433/4885NOS1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.